Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 21,021 Shares of Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc bought 21,021 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was bought at an average price of $14.07 per share, for a total transaction of $295,765.47. Following the completion of the purchase, the director now directly owns 15,206,980 shares in the company, valued at approximately $213,962,208.60. This represents a 0.14 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The stock was purchased at an average cost of $13.13 per share, for a total transaction of $2,679,806.74.
• On Thursday, January 2nd, Ecor1 Capital, Llc bought 157,880 shares of Zymeworks stock. The stock was purchased at an average price of $14.78 per share, with a total value of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc purchased 58,988 shares of Zymeworks stock. The shares were purchased at an average price of $14.47 per share, for a total transaction of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc bought 11,958 shares of Zymeworks stock. The shares were acquired at an average price of $14.12 per share, for a total transaction of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc purchased 16,692 shares of Zymeworks stock. The stock was acquired at an average price of $14.38 per share, with a total value of $240,030.96.

Zymeworks Trading Down 6.4 %

NYSE:ZYME opened at $13.22 on Friday. Zymeworks Inc. has a twelve month low of $7.97 and a twelve month high of $17.70. The company has a market cap of $910.57 million, a PE ratio of -8.81 and a beta of 1.10. The company’s 50 day moving average is $14.48 and its two-hundred day moving average is $12.39.

Zymeworks (NYSE:ZYME) last released its earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The firm had revenue of $16.00 million for the quarter, compared to the consensus estimate of $17.90 million. During the same period in the prior year, the firm earned ($0.41) EPS. The firm’s revenue was down 3.1% on a year-over-year basis. As a group, analysts expect that Zymeworks Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZYME. Wells Fargo & Company upped their target price on Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a report on Thursday, December 19th. Leerink Partnrs upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. HC Wainwright reiterated a “neutral” rating and issued a $12.00 target price on shares of Zymeworks in a research note on Friday, November 22nd. Citigroup increased their price target on shares of Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. raised shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective on the stock in a research report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.17.

Hedge Funds Weigh In On Zymeworks

Several hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its stake in Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after acquiring an additional 1,525 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in Zymeworks during the third quarter valued at $47,000. Quest Partners LLC boosted its holdings in Zymeworks by 8,049.6% in the second quarter. Quest Partners LLC now owns 9,209 shares of the company’s stock valued at $78,000 after purchasing an additional 9,096 shares during the last quarter. nVerses Capital LLC acquired a new stake in Zymeworks during the 3rd quarter worth about $79,000. Finally, MQS Management LLC purchased a new position in shares of Zymeworks during the 2nd quarter valued at about $92,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.